Sökning: "tyrosine kinase inhibitor"
Visar resultat 1 - 5 av 139 avhandlingar innehållade orden tyrosine kinase inhibitor.
1. Pharmaceutical Protection of Beta-Cells in Diabetes : Using Tyrosine Kinase Inhibition and NOX4 Inhibitors
Sammanfattning : Diabetes mellitus is a complex and heterogenous disease, with loss of beta-cell function and mass being a characteristic of not only type 1 diabetes (T1D), but also type 2 diabetes (T2D). In T1D, inappropriate inflammatory signaling is thought to participate in the autoimmune suppression and destruction of beta-cells. LÄS MER
2. Using Light to Regulate the Activity of RET Kinase: Design, synthesis and evaluation of photoswitchable DFG-out RET kinase inhibitors
Sammanfattning : Protein kinases are essential for signal transduction and regulate most cellular processes, such as metabolism, membrane transport, motility, and cell cycle. Although they play a critical role in cells and have a strong association with diseases, details of their physiologic and pathologic mechanisms remain at least partially unclear, especially the spatiotemporal dynamics of the signalling. LÄS MER
3. Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia
Sammanfattning : Chronic myeloid leukemia (CML) is caused by the tyrosine kinase activity of the oncoprotein BCR-ABL. The introduction of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has profoundly changed the prognosis of CML. Currently, there are three TKIs approved for treatment of CML, imatinib, nilotinib and dasatinib. LÄS MER
4. The FLT3 Tyrosine Kinase in Leukemia : Deciphering the Downstream Signaling Events and Drug-Escape Mechanisms
Sammanfattning : Acute myeloid leukemia (AML) is a severe disease, which originates in blood-forming cells. Although major advances in understanding the biology of AML, the majority of patients eventually succumb to the disease. LÄS MER
5. Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
Sammanfattning : Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first reported as a fusion partner of nucleophosmin in Anaplastic large cell lymphoma in 1994. ALK is involved in myriad of cancers including neuroblastoma which is the most common extracranial solid tumor affecting young children. LÄS MER